nodes	percent_of_prediction	percent_of_DWPC	metapath
Mianserin—CYP1A2—Anagrelide—hematologic cancer	0.0358	0.0675	CbGbCtD
Mianserin—CYP2B6—Thiotepa—hematologic cancer	0.0351	0.0661	CbGbCtD
Mianserin—CYP2B6—Ifosfamide—hematologic cancer	0.0199	0.0375	CbGbCtD
Mianserin—CYP2D6—Lomustine—hematologic cancer	0.019	0.0358	CbGbCtD
Mianserin—CYP1A2—Carmustine—hematologic cancer	0.0188	0.0354	CbGbCtD
Mianserin—CYP2B6—Nilotinib—hematologic cancer	0.0173	0.0326	CbGbCtD
Mianserin—CYP2D6—Idarubicin—hematologic cancer	0.017	0.0319	CbGbCtD
Mianserin—CYP1A2—Methoxsalen—hematologic cancer	0.016	0.0301	CbGbCtD
Mianserin—CYP1A2—Bortezomib—hematologic cancer	0.0152	0.0287	CbGbCtD
Mianserin—CYP1A2—Daunorubicin—hematologic cancer	0.0146	0.0274	CbGbCtD
Mianserin—CYP2D6—Hydroxyurea—hematologic cancer	0.0144	0.0272	CbGbCtD
Mianserin—CYP1A2—Alitretinoin—hematologic cancer	0.0143	0.0269	CbGbCtD
Mianserin—CYP1A2—Thalidomide—hematologic cancer	0.0133	0.025	CbGbCtD
Mianserin—CYP3A4—Bexarotene—hematologic cancer	0.013	0.0245	CbGbCtD
Mianserin—CYP2D6—Bortezomib—hematologic cancer	0.0125	0.0236	CbGbCtD
Mianserin—CYP3A4—Lomustine—hematologic cancer	0.0121	0.0228	CbGbCtD
Mianserin—CYP3A4—Busulfan—hematologic cancer	0.0121	0.0228	CbGbCtD
Mianserin—CYP2B6—Irinotecan—hematologic cancer	0.0119	0.0224	CbGbCtD
Mianserin—CYP1A2—Dacarbazine—hematologic cancer	0.0114	0.0215	CbGbCtD
Mianserin—CYP1A2—Imatinib—hematologic cancer	0.0111	0.021	CbGbCtD
Mianserin—CYP3A4—Thiotepa—hematologic cancer	0.0108	0.0203	CbGbCtD
Mianserin—CYP2B6—Cisplatin—hematologic cancer	0.00968	0.0182	CbGbCtD
Mianserin—CYP2D6—Imatinib—hematologic cancer	0.00919	0.0173	CbGbCtD
Mianserin—CYP1A2—Dasatinib—hematologic cancer	0.00896	0.0169	CbGbCtD
Mianserin—CYP3A4—Methoxsalen—hematologic cancer	0.00838	0.0158	CbGbCtD
Mianserin—CYP2D6—Nilotinib—hematologic cancer	0.00835	0.0157	CbGbCtD
Mianserin—CYP2D6—Vinorelbine—hematologic cancer	0.00828	0.0156	CbGbCtD
Mianserin—CYP3A4—Bortezomib—hematologic cancer	0.00797	0.015	CbGbCtD
Mianserin—CYP2B6—Dexamethasone—hematologic cancer	0.00782	0.0147	CbGbCtD
Mianserin—CYP3A4—Daunorubicin—hematologic cancer	0.00763	0.0144	CbGbCtD
Mianserin—CYP3A4—Cytarabine—hematologic cancer	0.00673	0.0127	CbGbCtD
Mianserin—CYP3A4—Teniposide—hematologic cancer	0.00663	0.0125	CbGbCtD
Mianserin—CYP2B6—Doxorubicin—hematologic cancer	0.00649	0.0122	CbGbCtD
Mianserin—CYP3A4—Ifosfamide—hematologic cancer	0.00612	0.0115	CbGbCtD
Mianserin—CYP3A4—Imatinib—hematologic cancer	0.00584	0.011	CbGbCtD
Mianserin—CYP1A2—Etoposide—hematologic cancer	0.00558	0.0105	CbGbCtD
Mianserin—CYP3A4—Ruxolitinib—hematologic cancer	0.0055	0.0104	CbGbCtD
Mianserin—CYP3A4—Nilotinib—hematologic cancer	0.00531	0.01	CbGbCtD
Mianserin—CYP3A4—Vinorelbine—hematologic cancer	0.00526	0.00992	CbGbCtD
Mianserin—CYP2D6—Vinblastine—hematologic cancer	0.0051	0.00961	CbGbCtD
Mianserin—CYP3A4—Triamcinolone—hematologic cancer	0.00481	0.00907	CbGbCtD
Mianserin—HRH4—hematopoietic system—hematologic cancer	0.00472	0.0996	CbGeAlD
Mianserin—CYP3A4—Dasatinib—hematologic cancer	0.00469	0.00884	CbGbCtD
Mianserin—CYP3A4—Mitoxantrone—hematologic cancer	0.00463	0.00873	CbGbCtD
Mianserin—CYP3A4—Betamethasone—hematologic cancer	0.00413	0.00778	CbGbCtD
Mianserin—CYP3A4—Prednisolone—hematologic cancer	0.00408	0.00768	CbGbCtD
Mianserin—CYP3A4—Prednisone—hematologic cancer	0.00385	0.00725	CbGbCtD
Mianserin—CYP2D6—Dexamethasone—hematologic cancer	0.00378	0.00712	CbGbCtD
Mianserin—CYP3A4—Irinotecan—hematologic cancer	0.00365	0.00687	CbGbCtD
Mianserin—CYP3A4—Vinblastine—hematologic cancer	0.00324	0.00611	CbGbCtD
Mianserin—CYP3A4—Vincristine—hematologic cancer	0.00319	0.00601	CbGbCtD
Mianserin—CYP2D6—Doxorubicin—hematologic cancer	0.00313	0.00591	CbGbCtD
Mianserin—HRH4—blood—hematologic cancer	0.00313	0.066	CbGeAlD
Mianserin—HRH4—bone marrow—hematologic cancer	0.00302	0.0638	CbGeAlD
Mianserin—CYP3A4—Etoposide—hematologic cancer	0.00292	0.00551	CbGbCtD
Mianserin—CYP3A4—Dexamethasone—hematologic cancer	0.0024	0.00453	CbGbCtD
Mianserin—CYP3A4—Doxorubicin—hematologic cancer	0.00199	0.00375	CbGbCtD
Mianserin—HRH2—hematopoietic system—hematologic cancer	0.00198	0.0418	CbGeAlD
Mianserin—HRH2—blood—hematologic cancer	0.00131	0.0277	CbGeAlD
Mianserin—SLC6A3—hematopoietic system—hematologic cancer	0.0013	0.0273	CbGeAlD
Mianserin—SLC6A4—hematopoietic system—hematologic cancer	0.00119	0.025	CbGeAlD
Mianserin—HRH2—lung—hematologic cancer	0.00115	0.0243	CbGeAlD
Mianserin—HTR1A—hematopoietic system—hematologic cancer	0.00105	0.0222	CbGeAlD
Mianserin—HTR7—hematopoietic system—hematologic cancer	0.00101	0.0213	CbGeAlD
Mianserin—CYP1A2—hematopoietic system—hematologic cancer	0.000803	0.017	CbGeAlD
Mianserin—SLC6A2—gonad—hematologic cancer	0.000794	0.0168	CbGeAlD
Mianserin—HRH2—lymph node—hematologic cancer	0.000787	0.0166	CbGeAlD
Mianserin—SLC6A4—blood—hematologic cancer	0.000786	0.0166	CbGeAlD
Mianserin—HTR2B—blood—hematologic cancer	0.000779	0.0164	CbGeAlD
Mianserin—CYP2B6—hematopoietic system—hematologic cancer	0.00077	0.0162	CbGeAlD
Mianserin—HTR7—gonad—hematologic cancer	0.000766	0.0162	CbGeAlD
Mianserin—SLC6A3—lung—hematologic cancer	0.000752	0.0159	CbGeAlD
Mianserin—HRH1—hematopoietic system—hematologic cancer	0.000752	0.0159	CbGeAlD
Mianserin—ADRA2A—hematopoietic system—hematologic cancer	0.000739	0.0156	CbGeAlD
Mianserin—SLC6A3—testis—hematologic cancer	0.00071	0.015	CbGeAlD
Mianserin—SLC6A4—lung—hematologic cancer	0.000689	0.0145	CbGeAlD
Mianserin—HTR2B—lung—hematologic cancer	0.000683	0.0144	CbGeAlD
Mianserin—HTR7—blood—hematologic cancer	0.000667	0.0141	CbGeAlD
Mianserin—HTR2A—hematopoietic system—hematologic cancer	0.000628	0.0133	CbGeAlD
Mianserin—ADRA2C—blood—hematologic cancer	0.000613	0.0129	CbGeAlD
Mianserin—SLC6A2—lung—hematologic cancer	0.000607	0.0128	CbGeAlD
Mianserin—CYP2B6—gonad—hematologic cancer	0.000585	0.0124	CbGeAlD
Mianserin—HTR7—lung—hematologic cancer	0.000585	0.0123	CbGeAlD
Mianserin—CYP3A4—hematopoietic system—hematologic cancer	0.000581	0.0123	CbGeAlD
Mianserin—SLC6A2—testis—hematologic cancer	0.000573	0.0121	CbGeAlD
Mianserin—CYP2D6—hematopoietic system—hematologic cancer	0.000572	0.0121	CbGeAlD
Mianserin—ADRA2A—gonad—hematologic cancer	0.000562	0.0119	CbGeAlD
Mianserin—DRD2—lung—hematologic cancer	0.000553	0.0117	CbGeAlD
Mianserin—HTR7—testis—hematologic cancer	0.000552	0.0116	CbGeAlD
Mianserin—ADRA2C—lung—hematologic cancer	0.000538	0.0113	CbGeAlD
Mianserin—CYP1A2—blood—hematologic cancer	0.000532	0.0112	CbGeAlD
Mianserin—DRD2—testis—hematologic cancer	0.000522	0.011	CbGeAlD
Mianserin—CYP2B6—blood—hematologic cancer	0.00051	0.0108	CbGeAlD
Mianserin—ADRA2C—testis—hematologic cancer	0.000507	0.0107	CbGeAlD
Mianserin—ADRA2A—blood—hematologic cancer	0.000489	0.0103	CbGeAlD
Mianserin—HTR2A—gonad—hematologic cancer	0.000477	0.0101	CbGeAlD
Mianserin—HTR2B—lymph node—hematologic cancer	0.000467	0.00986	CbGeAlD
Mianserin—CYP1A2—lung—hematologic cancer	0.000466	0.00985	CbGeAlD
Mianserin—CYP2B6—lung—hematologic cancer	0.000447	0.00944	CbGeAlD
Mianserin—HRH1—lung—hematologic cancer	0.000437	0.00922	CbGeAlD
Mianserin—ADRA2A—lung—hematologic cancer	0.000429	0.00905	CbGeAlD
Mianserin—CYP2B6—testis—hematologic cancer	0.000422	0.0089	CbGeAlD
Mianserin—HTR2A—blood—hematologic cancer	0.000416	0.00878	CbGeAlD
Mianserin—SLC6A2—lymph node—hematologic cancer	0.000415	0.00876	CbGeAlD
Mianserin—HRH1—testis—hematologic cancer	0.000412	0.0087	CbGeAlD
Mianserin—ADRA2A—testis—hematologic cancer	0.000405	0.00854	CbGeAlD
Mianserin—CYP3A4—blood—hematologic cancer	0.000385	0.00813	CbGeAlD
Mianserin—CYP2D6—blood—hematologic cancer	0.000379	0.008	CbGeAlD
Mianserin—ADRA2C—lymph node—hematologic cancer	0.000368	0.00776	CbGeAlD
Mianserin—HTR2A—lung—hematologic cancer	0.000365	0.0077	CbGeAlD
Mianserin—HTR2A—testis—hematologic cancer	0.000344	0.00726	CbGeAlD
Mianserin—CYP2D6—testis—hematologic cancer	0.000313	0.00662	CbGeAlD
Mianserin—HRH1—lymph node—hematologic cancer	0.000299	0.0063	CbGeAlD
Mianserin—ADRA2A—lymph node—hematologic cancer	0.000293	0.00619	CbGeAlD
Mianserin—Headache—Thiotepa—hematologic cancer	7.76e-05	0.000276	CcSEcCtD
Mianserin—Hypertension—Betamethasone—hematologic cancer	7.75e-05	0.000276	CcSEcCtD
Mianserin—Hypertension—Dexamethasone—hematologic cancer	7.75e-05	0.000276	CcSEcCtD
Mianserin—Pancytopenia—Doxorubicin—hematologic cancer	7.71e-05	0.000274	CcSEcCtD
Mianserin—Gastrointestinal disorder—Etoposide—hematologic cancer	7.69e-05	0.000273	CcSEcCtD
Mianserin—Asthenia—Irinotecan—hematologic cancer	7.68e-05	0.000273	CcSEcCtD
Mianserin—Asthenia—Mitoxantrone—hematologic cancer	7.68e-05	0.000273	CcSEcCtD
Mianserin—Fatigue—Etoposide—hematologic cancer	7.68e-05	0.000273	CcSEcCtD
Mianserin—Myalgia—Betamethasone—hematologic cancer	7.64e-05	0.000272	CcSEcCtD
Mianserin—Myalgia—Dexamethasone—hematologic cancer	7.64e-05	0.000272	CcSEcCtD
Mianserin—Jaundice—Epirubicin—hematologic cancer	7.63e-05	0.000271	CcSEcCtD
Mianserin—Dizziness—Carmustine—hematologic cancer	7.61e-05	0.000271	CcSEcCtD
Mianserin—Constipation—Etoposide—hematologic cancer	7.61e-05	0.000271	CcSEcCtD
Mianserin—Neutropenia—Doxorubicin—hematologic cancer	7.59e-05	0.00027	CcSEcCtD
Mianserin—Rash—Thalidomide—hematologic cancer	7.56e-05	0.000269	CcSEcCtD
Mianserin—Dermatitis—Thalidomide—hematologic cancer	7.55e-05	0.000269	CcSEcCtD
Mianserin—Dizziness—Alitretinoin—hematologic cancer	7.54e-05	0.000268	CcSEcCtD
Mianserin—Headache—Thalidomide—hematologic cancer	7.51e-05	0.000267	CcSEcCtD
Mianserin—Hepatitis—Methotrexate—hematologic cancer	7.51e-05	0.000267	CcSEcCtD
Mianserin—Asthenia—Gemcitabine—hematologic cancer	7.48e-05	0.000266	CcSEcCtD
Mianserin—Dizziness—Ifosfamide—hematologic cancer	7.45e-05	0.000265	CcSEcCtD
Mianserin—Hepatobiliary disease—Epirubicin—hematologic cancer	7.4e-05	0.000263	CcSEcCtD
Mianserin—Weight increased—Doxorubicin—hematologic cancer	7.39e-05	0.000263	CcSEcCtD
Mianserin—Pruritus—Gemcitabine—hematologic cancer	7.38e-05	0.000262	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Triamcinolone—hematologic cancer	7.36e-05	0.000262	CcSEcCtD
Mianserin—Feeling abnormal—Etoposide—hematologic cancer	7.34e-05	0.000261	CcSEcCtD
Mianserin—Oedema—Betamethasone—hematologic cancer	7.33e-05	0.000261	CcSEcCtD
Mianserin—Oedema—Dexamethasone—hematologic cancer	7.33e-05	0.000261	CcSEcCtD
Mianserin—Agranulocytosis—Epirubicin—hematologic cancer	7.3e-05	0.00026	CcSEcCtD
Mianserin—Dizziness—Vincristine—hematologic cancer	7.27e-05	0.000259	CcSEcCtD
Mianserin—Rash—Carmustine—hematologic cancer	7.26e-05	0.000258	CcSEcCtD
Mianserin—Desipramine—SLC22A1—hematologic cancer	7.25e-05	0.203	CrCbGaD
Mianserin—Dermatitis—Carmustine—hematologic cancer	7.25e-05	0.000258	CcSEcCtD
Mianserin—Paraesthesia—Triamcinolone—hematologic cancer	7.25e-05	0.000258	CcSEcCtD
Mianserin—Drowsiness—Doxorubicin—hematologic cancer	7.24e-05	0.000258	CcSEcCtD
Mianserin—Feeling abnormal—Prednisolone—hematologic cancer	7.24e-05	0.000257	CcSEcCtD
Mianserin—Anaemia—Prednisone—hematologic cancer	7.23e-05	0.000257	CcSEcCtD
Mianserin—Headache—Carmustine—hematologic cancer	7.21e-05	0.000257	CcSEcCtD
Mianserin—Shock—Dexamethasone—hematologic cancer	7.21e-05	0.000256	CcSEcCtD
Mianserin—Shock—Betamethasone—hematologic cancer	7.21e-05	0.000256	CcSEcCtD
Mianserin—Rash—Alitretinoin—hematologic cancer	7.19e-05	0.000256	CcSEcCtD
Mianserin—Nervous system disorder—Betamethasone—hematologic cancer	7.19e-05	0.000256	CcSEcCtD
Mianserin—Nervous system disorder—Dexamethasone—hematologic cancer	7.19e-05	0.000256	CcSEcCtD
Mianserin—Agitation—Prednisone—hematologic cancer	7.18e-05	0.000256	CcSEcCtD
Mianserin—Dermatitis—Alitretinoin—hematologic cancer	7.18e-05	0.000256	CcSEcCtD
Mianserin—Thrombocytopenia—Dexamethasone—hematologic cancer	7.17e-05	0.000255	CcSEcCtD
Mianserin—Thrombocytopenia—Betamethasone—hematologic cancer	7.17e-05	0.000255	CcSEcCtD
Mianserin—Tachycardia—Betamethasone—hematologic cancer	7.15e-05	0.000254	CcSEcCtD
Mianserin—Tachycardia—Dexamethasone—hematologic cancer	7.15e-05	0.000254	CcSEcCtD
Mianserin—Bradycardia—Epirubicin—hematologic cancer	7.15e-05	0.000254	CcSEcCtD
Mianserin—Headache—Alitretinoin—hematologic cancer	7.14e-05	0.000254	CcSEcCtD
Mianserin—Rash—Ifosfamide—hematologic cancer	7.11e-05	0.000253	CcSEcCtD
Mianserin—Dermatitis—Ifosfamide—hematologic cancer	7.1e-05	0.000253	CcSEcCtD
Mianserin—Dizziness—Irinotecan—hematologic cancer	7.08e-05	0.000252	CcSEcCtD
Mianserin—Jaundice—Doxorubicin—hematologic cancer	7.06e-05	0.000251	CcSEcCtD
Mianserin—Vertigo—Prednisone—hematologic cancer	7.02e-05	0.00025	CcSEcCtD
Mianserin—Hepatitis—Epirubicin—hematologic cancer	7.02e-05	0.00025	CcSEcCtD
Mianserin—Eye disorder—Methotrexate—hematologic cancer	7.01e-05	0.00025	CcSEcCtD
Mianserin—Syncope—Prednisone—hematologic cancer	7.01e-05	0.000249	CcSEcCtD
Mianserin—Tinnitus—Methotrexate—hematologic cancer	7e-05	0.000249	CcSEcCtD
Mianserin—Asthenia—Cisplatin—hematologic cancer	6.97e-05	0.000248	CcSEcCtD
Mianserin—Cardiac disorder—Methotrexate—hematologic cancer	6.97e-05	0.000248	CcSEcCtD
Mianserin—Fatigue—Triamcinolone—hematologic cancer	6.96e-05	0.000248	CcSEcCtD
Mianserin—Rash—Vincristine—hematologic cancer	6.93e-05	0.000246	CcSEcCtD
Mianserin—Dermatitis—Vincristine—hematologic cancer	6.92e-05	0.000246	CcSEcCtD
Mianserin—Connective tissue disorder—Epirubicin—hematologic cancer	6.9e-05	0.000246	CcSEcCtD
Mianserin—Headache—Vincristine—hematologic cancer	6.88e-05	0.000245	CcSEcCtD
Mianserin—Loss of consciousness—Prednisone—hematologic cancer	6.87e-05	0.000244	CcSEcCtD
Mianserin—Hepatobiliary disease—Doxorubicin—hematologic cancer	6.85e-05	0.000244	CcSEcCtD
Mianserin—Hypotension—Betamethasone—hematologic cancer	6.85e-05	0.000244	CcSEcCtD
Mianserin—Hypotension—Dexamethasone—hematologic cancer	6.85e-05	0.000244	CcSEcCtD
Mianserin—Angiopathy—Methotrexate—hematologic cancer	6.81e-05	0.000242	CcSEcCtD
Mianserin—Convulsion—Prednisone—hematologic cancer	6.77e-05	0.000241	CcSEcCtD
Mianserin—Mediastinal disorder—Methotrexate—hematologic cancer	6.76e-05	0.000241	CcSEcCtD
Mianserin—Agranulocytosis—Doxorubicin—hematologic cancer	6.76e-05	0.00024	CcSEcCtD
Mianserin—Hypertension—Prednisone—hematologic cancer	6.75e-05	0.00024	CcSEcCtD
Mianserin—Rash—Irinotecan—hematologic cancer	6.75e-05	0.00024	CcSEcCtD
Mianserin—Rash—Mitoxantrone—hematologic cancer	6.75e-05	0.00024	CcSEcCtD
Mianserin—Dermatitis—Irinotecan—hematologic cancer	6.74e-05	0.00024	CcSEcCtD
Mianserin—Dermatitis—Mitoxantrone—hematologic cancer	6.74e-05	0.00024	CcSEcCtD
Mianserin—Headache—Mitoxantrone—hematologic cancer	6.7e-05	0.000239	CcSEcCtD
Mianserin—Headache—Irinotecan—hematologic cancer	6.7e-05	0.000239	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	6.68e-05	0.000237	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Betamethasone—hematologic cancer	6.68e-05	0.000237	CcSEcCtD
Mianserin—Arthralgia—Prednisone—hematologic cancer	6.66e-05	0.000237	CcSEcCtD
Mianserin—Myalgia—Prednisone—hematologic cancer	6.66e-05	0.000237	CcSEcCtD
Mianserin—Feeling abnormal—Triamcinolone—hematologic cancer	6.65e-05	0.000237	CcSEcCtD
Mianserin—Bradycardia—Doxorubicin—hematologic cancer	6.62e-05	0.000235	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	6.61e-05	0.000235	CcSEcCtD
Mianserin—Paraesthesia—Betamethasone—hematologic cancer	6.58e-05	0.000234	CcSEcCtD
Mianserin—Paraesthesia—Dexamethasone—hematologic cancer	6.58e-05	0.000234	CcSEcCtD
Mianserin—Mental disorder—Methotrexate—hematologic cancer	6.58e-05	0.000234	CcSEcCtD
Mianserin—Rash—Gemcitabine—hematologic cancer	6.57e-05	0.000234	CcSEcCtD
Mianserin—Dermatitis—Gemcitabine—hematologic cancer	6.57e-05	0.000234	CcSEcCtD
Mianserin—Eye disorder—Epirubicin—hematologic cancer	6.56e-05	0.000234	CcSEcCtD
Mianserin—Tinnitus—Epirubicin—hematologic cancer	6.55e-05	0.000233	CcSEcCtD
Mianserin—Headache—Gemcitabine—hematologic cancer	6.53e-05	0.000232	CcSEcCtD
Mianserin—Cardiac disorder—Epirubicin—hematologic cancer	6.52e-05	0.000232	CcSEcCtD
Mianserin—Hepatitis—Doxorubicin—hematologic cancer	6.5e-05	0.000231	CcSEcCtD
Mianserin—Asthenia—Etoposide—hematologic cancer	6.39e-05	0.000227	CcSEcCtD
Mianserin—Connective tissue disorder—Doxorubicin—hematologic cancer	6.39e-05	0.000227	CcSEcCtD
Mianserin—Oedema—Prednisone—hematologic cancer	6.38e-05	0.000227	CcSEcCtD
Mianserin—Angiopathy—Epirubicin—hematologic cancer	6.37e-05	0.000227	CcSEcCtD
Mianserin—Mediastinal disorder—Epirubicin—hematologic cancer	6.33e-05	0.000225	CcSEcCtD
Mianserin—Gastrointestinal disorder—Betamethasone—hematologic cancer	6.33e-05	0.000225	CcSEcCtD
Mianserin—Gastrointestinal disorder—Dexamethasone—hematologic cancer	6.33e-05	0.000225	CcSEcCtD
Mianserin—Fatigue—Dexamethasone—hematologic cancer	6.32e-05	0.000225	CcSEcCtD
Mianserin—Fatigue—Betamethasone—hematologic cancer	6.32e-05	0.000225	CcSEcCtD
Mianserin—Pruritus—Etoposide—hematologic cancer	6.3e-05	0.000224	CcSEcCtD
Mianserin—Shock—Prednisone—hematologic cancer	6.28e-05	0.000223	CcSEcCtD
Mianserin—Nervous system disorder—Prednisone—hematologic cancer	6.26e-05	0.000223	CcSEcCtD
Mianserin—Tachycardia—Prednisone—hematologic cancer	6.23e-05	0.000222	CcSEcCtD
Mianserin—Skin disorder—Prednisone—hematologic cancer	6.2e-05	0.00022	CcSEcCtD
Mianserin—Mental disorder—Epirubicin—hematologic cancer	6.15e-05	0.000219	CcSEcCtD
Mianserin—Imipramine—SLC22A1—hematologic cancer	6.15e-05	0.172	CrCbGaD
Mianserin—Rash—Cisplatin—hematologic cancer	6.13e-05	0.000218	CcSEcCtD
Mianserin—Dermatitis—Cisplatin—hematologic cancer	6.12e-05	0.000218	CcSEcCtD
Mianserin—Eye disorder—Doxorubicin—hematologic cancer	6.07e-05	0.000216	CcSEcCtD
Mianserin—Tinnitus—Doxorubicin—hematologic cancer	6.06e-05	0.000216	CcSEcCtD
Mianserin—Anaemia—Methotrexate—hematologic cancer	6.04e-05	0.000215	CcSEcCtD
Mianserin—Feeling abnormal—Dexamethasone—hematologic cancer	6.04e-05	0.000215	CcSEcCtD
Mianserin—Feeling abnormal—Betamethasone—hematologic cancer	6.04e-05	0.000215	CcSEcCtD
Mianserin—Cardiac disorder—Doxorubicin—hematologic cancer	6.03e-05	0.000215	CcSEcCtD
Mianserin—Angiopathy—Doxorubicin—hematologic cancer	5.9e-05	0.00021	CcSEcCtD
Mianserin—Dizziness—Etoposide—hematologic cancer	5.89e-05	0.000209	CcSEcCtD
Mianserin—Vertigo—Methotrexate—hematologic cancer	5.87e-05	0.000209	CcSEcCtD
Mianserin—Mediastinal disorder—Doxorubicin—hematologic cancer	5.86e-05	0.000208	CcSEcCtD
Mianserin—Leukopenia—Methotrexate—hematologic cancer	5.85e-05	0.000208	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Prednisone—hematologic cancer	5.81e-05	0.000207	CcSEcCtD
Mianserin—Dizziness—Prednisolone—hematologic cancer	5.81e-05	0.000207	CcSEcCtD
Mianserin—Asthenia—Triamcinolone—hematologic cancer	5.79e-05	0.000206	CcSEcCtD
Mianserin—Paraesthesia—Prednisone—hematologic cancer	5.73e-05	0.000204	CcSEcCtD
Mianserin—Pruritus—Triamcinolone—hematologic cancer	5.71e-05	0.000203	CcSEcCtD
Mianserin—Mental disorder—Doxorubicin—hematologic cancer	5.69e-05	0.000203	CcSEcCtD
Mianserin—Convulsion—Methotrexate—hematologic cancer	5.66e-05	0.000201	CcSEcCtD
Mianserin—Anaemia—Epirubicin—hematologic cancer	5.65e-05	0.000201	CcSEcCtD
Mianserin—Agitation—Epirubicin—hematologic cancer	5.62e-05	0.0002	CcSEcCtD
Mianserin—Rash—Etoposide—hematologic cancer	5.61e-05	0.0002	CcSEcCtD
Mianserin—Dermatitis—Etoposide—hematologic cancer	5.61e-05	0.000199	CcSEcCtD
Mianserin—Headache—Etoposide—hematologic cancer	5.58e-05	0.000198	CcSEcCtD
Mianserin—Myalgia—Methotrexate—hematologic cancer	5.56e-05	0.000198	CcSEcCtD
Mianserin—Arthralgia—Methotrexate—hematologic cancer	5.56e-05	0.000198	CcSEcCtD
Mianserin—Rash—Prednisolone—hematologic cancer	5.54e-05	0.000197	CcSEcCtD
Mianserin—Dermatitis—Prednisolone—hematologic cancer	5.53e-05	0.000197	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	5.52e-05	0.000197	CcSEcCtD
Mianserin—Fatigue—Prednisone—hematologic cancer	5.5e-05	0.000196	CcSEcCtD
Mianserin—Headache—Prednisolone—hematologic cancer	5.5e-05	0.000196	CcSEcCtD
Mianserin—Vertigo—Epirubicin—hematologic cancer	5.49e-05	0.000195	CcSEcCtD
Mianserin—Syncope—Epirubicin—hematologic cancer	5.48e-05	0.000195	CcSEcCtD
Mianserin—Leukopenia—Epirubicin—hematologic cancer	5.47e-05	0.000195	CcSEcCtD
Mianserin—Constipation—Prednisone—hematologic cancer	5.46e-05	0.000194	CcSEcCtD
Mianserin—Confusional state—Methotrexate—hematologic cancer	5.38e-05	0.000191	CcSEcCtD
Mianserin—Loss of consciousness—Epirubicin—hematologic cancer	5.37e-05	0.000191	CcSEcCtD
Mianserin—Dizziness—Triamcinolone—hematologic cancer	5.34e-05	0.00019	CcSEcCtD
Mianserin—Convulsion—Epirubicin—hematologic cancer	5.3e-05	0.000188	CcSEcCtD
Mianserin—Hypertension—Epirubicin—hematologic cancer	5.28e-05	0.000188	CcSEcCtD
Mianserin—Feeling abnormal—Prednisone—hematologic cancer	5.26e-05	0.000187	CcSEcCtD
Mianserin—Asthenia—Dexamethasone—hematologic cancer	5.26e-05	0.000187	CcSEcCtD
Mianserin—Asthenia—Betamethasone—hematologic cancer	5.26e-05	0.000187	CcSEcCtD
Mianserin—Nervous system disorder—Methotrexate—hematologic cancer	5.23e-05	0.000186	CcSEcCtD
Mianserin—Anaemia—Doxorubicin—hematologic cancer	5.23e-05	0.000186	CcSEcCtD
Mianserin—Thrombocytopenia—Methotrexate—hematologic cancer	5.22e-05	0.000186	CcSEcCtD
Mianserin—Arthralgia—Epirubicin—hematologic cancer	5.21e-05	0.000185	CcSEcCtD
Mianserin—Myalgia—Epirubicin—hematologic cancer	5.21e-05	0.000185	CcSEcCtD
Mianserin—Agitation—Doxorubicin—hematologic cancer	5.2e-05	0.000185	CcSEcCtD
Mianserin—Pruritus—Dexamethasone—hematologic cancer	5.18e-05	0.000184	CcSEcCtD
Mianserin—Pruritus—Betamethasone—hematologic cancer	5.18e-05	0.000184	CcSEcCtD
Mianserin—Skin disorder—Methotrexate—hematologic cancer	5.18e-05	0.000184	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	5.17e-05	0.000184	CcSEcCtD
Mianserin—Rash—Triamcinolone—hematologic cancer	5.09e-05	0.000181	CcSEcCtD
Mianserin—Dry mouth—Epirubicin—hematologic cancer	5.09e-05	0.000181	CcSEcCtD
Mianserin—Dermatitis—Triamcinolone—hematologic cancer	5.09e-05	0.000181	CcSEcCtD
Mianserin—Vertigo—Doxorubicin—hematologic cancer	5.08e-05	0.000181	CcSEcCtD
Mianserin—Syncope—Doxorubicin—hematologic cancer	5.07e-05	0.00018	CcSEcCtD
Mianserin—Leukopenia—Doxorubicin—hematologic cancer	5.06e-05	0.00018	CcSEcCtD
Mianserin—Headache—Triamcinolone—hematologic cancer	5.06e-05	0.00018	CcSEcCtD
Mianserin—Confusional state—Epirubicin—hematologic cancer	5.03e-05	0.000179	CcSEcCtD
Mianserin—Oedema—Epirubicin—hematologic cancer	4.99e-05	0.000178	CcSEcCtD
Mianserin—Hypotension—Methotrexate—hematologic cancer	4.98e-05	0.000177	CcSEcCtD
Mianserin—Loss of consciousness—Doxorubicin—hematologic cancer	4.97e-05	0.000177	CcSEcCtD
Mianserin—Epinastine—ABCB1—hematologic cancer	4.95e-05	0.138	CrCbGaD
Mianserin—Shock—Epirubicin—hematologic cancer	4.91e-05	0.000175	CcSEcCtD
Mianserin—Convulsion—Doxorubicin—hematologic cancer	4.9e-05	0.000174	CcSEcCtD
Mianserin—Nervous system disorder—Epirubicin—hematologic cancer	4.89e-05	0.000174	CcSEcCtD
Mianserin—Thrombocytopenia—Epirubicin—hematologic cancer	4.89e-05	0.000174	CcSEcCtD
Mianserin—Hypertension—Doxorubicin—hematologic cancer	4.88e-05	0.000174	CcSEcCtD
Mianserin—Tachycardia—Epirubicin—hematologic cancer	4.87e-05	0.000173	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Methotrexate—hematologic cancer	4.86e-05	0.000173	CcSEcCtD
Mianserin—Skin disorder—Epirubicin—hematologic cancer	4.85e-05	0.000172	CcSEcCtD
Mianserin—Dizziness—Dexamethasone—hematologic cancer	4.84e-05	0.000172	CcSEcCtD
Mianserin—Dizziness—Betamethasone—hematologic cancer	4.84e-05	0.000172	CcSEcCtD
Mianserin—Myalgia—Doxorubicin—hematologic cancer	4.82e-05	0.000171	CcSEcCtD
Mianserin—Arthralgia—Doxorubicin—hematologic cancer	4.82e-05	0.000171	CcSEcCtD
Mianserin—Paraesthesia—Methotrexate—hematologic cancer	4.79e-05	0.00017	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	4.78e-05	0.00017	CcSEcCtD
Mianserin—Oxcarbazepine—ALB—hematologic cancer	4.78e-05	0.134	CrCbGaD
Mianserin—Somnolence—Methotrexate—hematologic cancer	4.74e-05	0.000169	CcSEcCtD
Mianserin—Dry mouth—Doxorubicin—hematologic cancer	4.71e-05	0.000168	CcSEcCtD
Mianserin—Hypotension—Epirubicin—hematologic cancer	4.66e-05	0.000166	CcSEcCtD
Mianserin—Confusional state—Doxorubicin—hematologic cancer	4.66e-05	0.000166	CcSEcCtD
Mianserin—Rash—Dexamethasone—hematologic cancer	4.62e-05	0.000164	CcSEcCtD
Mianserin—Rash—Betamethasone—hematologic cancer	4.62e-05	0.000164	CcSEcCtD
Mianserin—Oedema—Doxorubicin—hematologic cancer	4.62e-05	0.000164	CcSEcCtD
Mianserin—Dermatitis—Betamethasone—hematologic cancer	4.62e-05	0.000164	CcSEcCtD
Mianserin—Dermatitis—Dexamethasone—hematologic cancer	4.62e-05	0.000164	CcSEcCtD
Mianserin—Gastrointestinal disorder—Methotrexate—hematologic cancer	4.6e-05	0.000164	CcSEcCtD
Mianserin—Fatigue—Methotrexate—hematologic cancer	4.6e-05	0.000164	CcSEcCtD
Mianserin—Headache—Dexamethasone—hematologic cancer	4.59e-05	0.000163	CcSEcCtD
Mianserin—Headache—Betamethasone—hematologic cancer	4.59e-05	0.000163	CcSEcCtD
Mianserin—Asthenia—Prednisone—hematologic cancer	4.58e-05	0.000163	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Epirubicin—hematologic cancer	4.55e-05	0.000162	CcSEcCtD
Mianserin—Shock—Doxorubicin—hematologic cancer	4.54e-05	0.000162	CcSEcCtD
Mianserin—Nervous system disorder—Doxorubicin—hematologic cancer	4.53e-05	0.000161	CcSEcCtD
Mianserin—Thrombocytopenia—Doxorubicin—hematologic cancer	4.52e-05	0.000161	CcSEcCtD
Mianserin—Pruritus—Prednisone—hematologic cancer	4.51e-05	0.000161	CcSEcCtD
Mianserin—Tachycardia—Doxorubicin—hematologic cancer	4.51e-05	0.00016	CcSEcCtD
Mianserin—Skin disorder—Doxorubicin—hematologic cancer	4.48e-05	0.00016	CcSEcCtD
Mianserin—Paraesthesia—Epirubicin—hematologic cancer	4.48e-05	0.000159	CcSEcCtD
Mianserin—Somnolence—Epirubicin—hematologic cancer	4.44e-05	0.000158	CcSEcCtD
Mianserin—Feeling abnormal—Methotrexate—hematologic cancer	4.39e-05	0.000156	CcSEcCtD
Mianserin—Hypotension—Doxorubicin—hematologic cancer	4.31e-05	0.000153	CcSEcCtD
Mianserin—Gastrointestinal disorder—Epirubicin—hematologic cancer	4.31e-05	0.000153	CcSEcCtD
Mianserin—Fatigue—Epirubicin—hematologic cancer	4.3e-05	0.000153	CcSEcCtD
Mianserin—Constipation—Epirubicin—hematologic cancer	4.27e-05	0.000152	CcSEcCtD
Mianserin—Dizziness—Prednisone—hematologic cancer	4.22e-05	0.00015	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	4.21e-05	0.00015	CcSEcCtD
Mianserin—Paraesthesia—Doxorubicin—hematologic cancer	4.15e-05	0.000147	CcSEcCtD
Mianserin—Feeling abnormal—Epirubicin—hematologic cancer	4.11e-05	0.000146	CcSEcCtD
Mianserin—Somnolence—Doxorubicin—hematologic cancer	4.1e-05	0.000146	CcSEcCtD
Mianserin—Rash—Prednisone—hematologic cancer	4.02e-05	0.000143	CcSEcCtD
Mianserin—Dermatitis—Prednisone—hematologic cancer	4.02e-05	0.000143	CcSEcCtD
Mianserin—Headache—Prednisone—hematologic cancer	4e-05	0.000142	CcSEcCtD
Mianserin—Gastrointestinal disorder—Doxorubicin—hematologic cancer	3.99e-05	0.000142	CcSEcCtD
Mianserin—Fatigue—Doxorubicin—hematologic cancer	3.98e-05	0.000142	CcSEcCtD
Mianserin—Constipation—Doxorubicin—hematologic cancer	3.95e-05	0.00014	CcSEcCtD
Mianserin—Asthenia—Methotrexate—hematologic cancer	3.83e-05	0.000136	CcSEcCtD
Mianserin—Feeling abnormal—Doxorubicin—hematologic cancer	3.8e-05	0.000135	CcSEcCtD
Mianserin—Pruritus—Methotrexate—hematologic cancer	3.77e-05	0.000134	CcSEcCtD
Mianserin—Asthenia—Epirubicin—hematologic cancer	3.58e-05	0.000127	CcSEcCtD
Mianserin—Pruritus—Epirubicin—hematologic cancer	3.53e-05	0.000126	CcSEcCtD
Mianserin—Dizziness—Methotrexate—hematologic cancer	3.53e-05	0.000125	CcSEcCtD
Mianserin—Rash—Methotrexate—hematologic cancer	3.36e-05	0.00012	CcSEcCtD
Mianserin—Dermatitis—Methotrexate—hematologic cancer	3.36e-05	0.000119	CcSEcCtD
Mianserin—Headache—Methotrexate—hematologic cancer	3.34e-05	0.000119	CcSEcCtD
Mianserin—Asthenia—Doxorubicin—hematologic cancer	3.31e-05	0.000118	CcSEcCtD
Mianserin—Dizziness—Epirubicin—hematologic cancer	3.3e-05	0.000117	CcSEcCtD
Mianserin—Pruritus—Doxorubicin—hematologic cancer	3.27e-05	0.000116	CcSEcCtD
Mianserin—Rash—Epirubicin—hematologic cancer	3.15e-05	0.000112	CcSEcCtD
Mianserin—Dermatitis—Epirubicin—hematologic cancer	3.14e-05	0.000112	CcSEcCtD
Mianserin—Headache—Epirubicin—hematologic cancer	3.13e-05	0.000111	CcSEcCtD
Mianserin—Dizziness—Doxorubicin—hematologic cancer	3.05e-05	0.000109	CcSEcCtD
Mianserin—Rash—Doxorubicin—hematologic cancer	2.91e-05	0.000104	CcSEcCtD
Mianserin—Dermatitis—Doxorubicin—hematologic cancer	2.91e-05	0.000103	CcSEcCtD
Mianserin—Headache—Doxorubicin—hematologic cancer	2.89e-05	0.000103	CcSEcCtD
Mianserin—Nortriptyline—ALB—hematologic cancer	2.68e-05	0.075	CrCbGaD
Mianserin—Trimipramine—ABCB1—hematologic cancer	2.41e-05	0.0674	CrCbGaD
Mianserin—Desipramine—ABCB1—hematologic cancer	2.11e-05	0.059	CrCbGaD
Mianserin—Amitriptyline—ALB—hematologic cancer	1.86e-05	0.0521	CrCbGaD
Mianserin—Imipramine—ABCB1—hematologic cancer	1.79e-05	0.05	CrCbGaD
Mianserin—Amitriptyline—ABCB1—hematologic cancer	1.78e-05	0.0497	CrCbGaD
Mianserin—HTR2C—Signaling by GPCR—AKT1—hematologic cancer	2.31e-06	1.65e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling by GPCR—HRAS—hematologic cancer	2.31e-06	1.65e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—CDKN1A—hematologic cancer	2.31e-06	1.65e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—PTEN—hematologic cancer	2.31e-06	1.64e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—PIK3CA—hematologic cancer	2.3e-06	1.64e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—SRC—hematologic cancer	2.29e-06	1.63e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—JAK2—hematologic cancer	2.28e-06	1.63e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—HRAS—hematologic cancer	2.27e-06	1.62e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—EP300—hematologic cancer	2.27e-06	1.62e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CDKN1B—hematologic cancer	2.27e-06	1.62e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—MYC—hematologic cancer	2.27e-06	1.62e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—PIK3CA—hematologic cancer	2.27e-06	1.62e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—HRAS—hematologic cancer	2.27e-06	1.62e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—PIK3CA—hematologic cancer	2.27e-06	1.62e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—TGFB1—hematologic cancer	2.27e-06	1.62e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—EP300—hematologic cancer	2.26e-06	1.61e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—KRAS—hematologic cancer	2.26e-06	1.61e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—MAPK8—hematologic cancer	2.26e-06	1.61e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—PIK3CA—hematologic cancer	2.25e-06	1.61e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling by GPCR—AKT1—hematologic cancer	2.25e-06	1.6e-05	CbGpPWpGaD
Mianserin—DRD2—GPCR downstream signaling—AKT1—hematologic cancer	2.25e-06	1.6e-05	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—PTEN—hematologic cancer	2.24e-06	1.6e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—PIK3CA—hematologic cancer	2.24e-06	1.59e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CDKN1B—hematologic cancer	2.24e-06	1.59e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CDKN1B—hematologic cancer	2.23e-06	1.59e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—VEGFA—hematologic cancer	2.23e-06	1.59e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—TP53—hematologic cancer	2.23e-06	1.59e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MDM2—hematologic cancer	2.23e-06	1.59e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CASP3—hematologic cancer	2.23e-06	1.59e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—IL2—hematologic cancer	2.22e-06	1.58e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—MTHFR—hematologic cancer	2.22e-06	1.58e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling by GPCR—IL6—hematologic cancer	2.21e-06	1.58e-05	CbGpPWpGaD
Mianserin—HTR2A—GPCR downstream signaling—AKT1—hematologic cancer	2.21e-06	1.58e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—SRC—hematologic cancer	2.21e-06	1.57e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—STAT3—hematologic cancer	2.21e-06	1.57e-05	CbGpPWpGaD
Mianserin—HRH1—GPCR downstream signaling—AKT1—hematologic cancer	2.21e-06	1.57e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PIK3CG—hematologic cancer	2.2e-06	1.57e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—NRAS—hematologic cancer	2.2e-06	1.57e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—EP300—hematologic cancer	2.2e-06	1.57e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—SRC—hematologic cancer	2.2e-06	1.57e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—TP53—hematologic cancer	2.2e-06	1.57e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—TP53—hematologic cancer	2.19e-06	1.56e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CASP3—hematologic cancer	2.19e-06	1.56e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—IL2—hematologic cancer	2.19e-06	1.56e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CASP3—hematologic cancer	2.19e-06	1.56e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—IL2—hematologic cancer	2.18e-06	1.56e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—TP53—hematologic cancer	2.18e-06	1.55e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—IL6—hematologic cancer	2.18e-06	1.55e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—IL6—hematologic cancer	2.17e-06	1.55e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CCND1—hematologic cancer	2.17e-06	1.54e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MTOR—hematologic cancer	2.17e-06	1.54e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—PIK3CB—hematologic cancer	2.17e-06	1.54e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—JUN—hematologic cancer	2.16e-06	1.54e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—VEGFA—hematologic cancer	2.15e-06	1.53e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—VEGFA—hematologic cancer	2.14e-06	1.53e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—SRC—hematologic cancer	2.14e-06	1.52e-05	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—EP300—hematologic cancer	2.14e-06	1.52e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CCND1—hematologic cancer	2.13e-06	1.52e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—HRAS—hematologic cancer	2.13e-06	1.52e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—STAT3—hematologic cancer	2.13e-06	1.52e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—JUN—hematologic cancer	2.13e-06	1.52e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CCND1—hematologic cancer	2.13e-06	1.52e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—NRAS—hematologic cancer	2.13e-06	1.51e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—JUN—hematologic cancer	2.12e-06	1.51e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—STAT3—hematologic cancer	2.12e-06	1.51e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—NRAS—hematologic cancer	2.11e-06	1.51e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—GSTP1—hematologic cancer	2.11e-06	1.51e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—MAPK3—hematologic cancer	2.11e-06	1.5e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—HRAS—hematologic cancer	2.1e-06	1.5e-05	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—PTEN—hematologic cancer	2.1e-06	1.5e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—KRAS—hematologic cancer	2.1e-06	1.5e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—HRAS—hematologic cancer	2.1e-06	1.5e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CDKN1A—hematologic cancer	2.1e-06	1.49e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—PTEN—hematologic cancer	2.09e-06	1.49e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—HRAS—hematologic cancer	2.08e-06	1.49e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—VEGFA—hematologic cancer	2.08e-06	1.48e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—PIK3CA—hematologic cancer	2.07e-06	1.48e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—HRAS—hematologic cancer	2.07e-06	1.47e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CDKN1A—hematologic cancer	2.06e-06	1.47e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—STAT3—hematologic cancer	2.06e-06	1.47e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CDKN1A—hematologic cancer	2.06e-06	1.47e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—PTEN—hematologic cancer	2.06e-06	1.47e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—NRAS—hematologic cancer	2.06e-06	1.47e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—PTEN—hematologic cancer	2.05e-06	1.46e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—MYC—hematologic cancer	2.05e-06	1.46e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—MAPK8—hematologic cancer	2.05e-06	1.46e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—TGFB1—hematologic cancer	2.05e-06	1.46e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—CREBBP—hematologic cancer	2.04e-06	1.46e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling by GPCR—AKT1—hematologic cancer	2.04e-06	1.45e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—IL6—hematologic cancer	2.04e-06	1.45e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—MAPK3—hematologic cancer	2.04e-06	1.45e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CDKN1B—hematologic cancer	2.03e-06	1.45e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—MAPK3—hematologic cancer	2.03e-06	1.44e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—MAPK8—hematologic cancer	2.01e-06	1.44e-05	CbGpPWpGaD
Mianserin—ADRA2A—GPCR downstream signaling—AKT1—hematologic cancer	2.01e-06	1.43e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—IL6—hematologic cancer	2.01e-06	1.43e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—MAPK8—hematologic cancer	2.01e-06	1.43e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—IL6—hematologic cancer	2.01e-06	1.43e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—AKT1—hematologic cancer	2.01e-06	1.43e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—TP53—hematologic cancer	2.01e-06	1.43e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—AKT1—hematologic cancer	2e-06	1.43e-05	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—EP300—hematologic cancer	2e-06	1.43e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—ABCB1—hematologic cancer	2e-06	1.42e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—IL6—hematologic cancer	2e-06	1.42e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—EP300—hematologic cancer	1.99e-06	1.42e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CASP3—hematologic cancer	1.99e-06	1.42e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—IL2—hematologic cancer	1.99e-06	1.42e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—IL6—hematologic cancer	1.98e-06	1.41e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—MYC—hematologic cancer	1.98e-06	1.41e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—TGFB1—hematologic cancer	1.98e-06	1.41e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—MAPK3—hematologic cancer	1.97e-06	1.4e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—MYC—hematologic cancer	1.97e-06	1.4e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—TGFB1—hematologic cancer	1.97e-06	1.4e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—EP300—hematologic cancer	1.96e-06	1.4e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—EP300—hematologic cancer	1.96e-06	1.4e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.96e-06	1.4e-05	CbGpPWpGaD
Mianserin—ADRA2C—Metabolism—PIK3CA—hematologic cancer	1.95e-06	1.39e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.94e-06	1.38e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.94e-06	1.38e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CCND1—hematologic cancer	1.94e-06	1.38e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—SRC—hematologic cancer	1.94e-06	1.38e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PIK3CD—hematologic cancer	1.94e-06	1.38e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—JUN—hematologic cancer	1.94e-06	1.38e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—PIK3CA—hematologic cancer	1.93e-06	1.37e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—HRAS—hematologic cancer	1.92e-06	1.37e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—MYC—hematologic cancer	1.92e-06	1.37e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—ALB—hematologic cancer	1.91e-06	1.36e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—TGFB1—hematologic cancer	1.91e-06	1.36e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—SRC—hematologic cancer	1.91e-06	1.36e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—SRC—hematologic cancer	1.9e-06	1.36e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—KRAS—hematologic cancer	1.9e-06	1.35e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—VEGFA—hematologic cancer	1.89e-06	1.35e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—AKT1—hematologic cancer	1.88e-06	1.34e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CDKN1A—hematologic cancer	1.88e-06	1.34e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—PTEN—hematologic cancer	1.87e-06	1.33e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—STAT3—hematologic cancer	1.87e-06	1.33e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PIK3CG—hematologic cancer	1.87e-06	1.33e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—NRAS—hematologic cancer	1.87e-06	1.33e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—TP53—hematologic cancer	1.87e-06	1.33e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—VEGFA—hematologic cancer	1.86e-06	1.32e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—VEGFA—hematologic cancer	1.86e-06	1.32e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—AKT1—hematologic cancer	1.85e-06	1.32e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—AKT1—hematologic cancer	1.85e-06	1.32e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—AKT1—hematologic cancer	1.84e-06	1.31e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—STAT3—hematologic cancer	1.84e-06	1.31e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—STAT3—hematologic cancer	1.84e-06	1.31e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—NRAS—hematologic cancer	1.84e-06	1.31e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—IL6—hematologic cancer	1.84e-06	1.31e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—NRAS—hematologic cancer	1.83e-06	1.31e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MAPK8—hematologic cancer	1.83e-06	1.31e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PIK3R1—hematologic cancer	1.83e-06	1.3e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—KRAS—hematologic cancer	1.83e-06	1.3e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—AKT1—hematologic cancer	1.83e-06	1.3e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—KRAS—hematologic cancer	1.82e-06	1.3e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—MAPK3—hematologic cancer	1.79e-06	1.27e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—EP300—hematologic cancer	1.79e-06	1.27e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—HRAS—hematologic cancer	1.78e-06	1.27e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—KRAS—hematologic cancer	1.77e-06	1.26e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—MAPK3—hematologic cancer	1.76e-06	1.25e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—MAPK3—hematologic cancer	1.75e-06	1.25e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—PIK3CA—hematologic cancer	1.74e-06	1.24e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—MYC—hematologic cancer	1.74e-06	1.24e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—SRC—hematologic cancer	1.74e-06	1.24e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—TGFB1—hematologic cancer	1.73e-06	1.24e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—CREBBP—hematologic cancer	1.73e-06	1.23e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.72e-06	1.22e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—MYC—hematologic cancer	1.71e-06	1.22e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—IL6—hematologic cancer	1.71e-06	1.22e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—MYC—hematologic cancer	1.71e-06	1.22e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—TGFB1—hematologic cancer	1.71e-06	1.22e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—TGFB1—hematologic cancer	1.7e-06	1.21e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—AKT1—hematologic cancer	1.69e-06	1.21e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—VEGFA—hematologic cancer	1.69e-06	1.21e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PIK3CB—hematologic cancer	1.69e-06	1.2e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—TP53—hematologic cancer	1.68e-06	1.2e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—PIK3CA—hematologic cancer	1.68e-06	1.2e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—STAT3—hematologic cancer	1.67e-06	1.19e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—PIK3CA—hematologic cancer	1.67e-06	1.19e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—NRAS—hematologic cancer	1.67e-06	1.19e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PIK3CD—hematologic cancer	1.64e-06	1.17e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—PIK3CA—hematologic cancer	1.63e-06	1.16e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—TP53—hematologic cancer	1.63e-06	1.16e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—ALB—hematologic cancer	1.62e-06	1.15e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—TP53—hematologic cancer	1.62e-06	1.15e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—HRAS—hematologic cancer	1.61e-06	1.15e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—KRAS—hematologic cancer	1.61e-06	1.14e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MAPK3—hematologic cancer	1.6e-06	1.14e-05	CbGpPWpGaD
Mianserin—ADRA2C—Metabolism—AKT1—hematologic cancer	1.59e-06	1.13e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—KRAS—hematologic cancer	1.58e-06	1.13e-05	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—PIK3CA—hematologic cancer	1.58e-06	1.13e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—KRAS—hematologic cancer	1.58e-06	1.12e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—AKT1—hematologic cancer	1.58e-06	1.12e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—TP53—hematologic cancer	1.57e-06	1.12e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MYC—hematologic cancer	1.56e-06	1.11e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—HRAS—hematologic cancer	1.56e-06	1.11e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—TGFB1—hematologic cancer	1.55e-06	1.11e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PIK3R1—hematologic cancer	1.55e-06	1.1e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—HRAS—hematologic cancer	1.55e-06	1.1e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—IL6—hematologic cancer	1.54e-06	1.1e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—HRAS—hematologic cancer	1.5e-06	1.07e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—IL6—hematologic cancer	1.49e-06	1.06e-05	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—PIK3CA—hematologic cancer	1.48e-06	1.06e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—IL6—hematologic cancer	1.48e-06	1.06e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—PIK3CA—hematologic cancer	1.48e-06	1.05e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PTEN—hematologic cancer	1.46e-06	1.04e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—PIK3CA—hematologic cancer	1.45e-06	1.03e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—PIK3CA—hematologic cancer	1.45e-06	1.03e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.44e-06	1.03e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—IL6—hematologic cancer	1.44e-06	1.03e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—KRAS—hematologic cancer	1.44e-06	1.02e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PIK3CB—hematologic cancer	1.43e-06	1.02e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—TP53—hematologic cancer	1.43e-06	1.02e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—AKT1—hematologic cancer	1.42e-06	1.01e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—TP53—hematologic cancer	1.4e-06	1e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—TP53—hematologic cancer	1.4e-06	9.99e-06	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—EP300—hematologic cancer	1.39e-06	9.92e-06	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—AKT1—hematologic cancer	1.37e-06	9.79e-06	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—AKT1—hematologic cancer	1.37e-06	9.74e-06	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—HRAS—hematologic cancer	1.37e-06	9.73e-06	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—HRAS—hematologic cancer	1.34e-06	9.57e-06	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—HRAS—hematologic cancer	1.34e-06	9.55e-06	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.34e-06	9.52e-06	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—AKT1—hematologic cancer	1.33e-06	9.47e-06	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—PIK3CA—hematologic cancer	1.32e-06	9.41e-06	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—IL6—hematologic cancer	1.31e-06	9.31e-06	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—AKT1—hematologic cancer	1.29e-06	9.2e-06	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—IL6—hematologic cancer	1.29e-06	9.16e-06	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—IL6—hematologic cancer	1.28e-06	9.14e-06	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—TP53—hematologic cancer	1.28e-06	9.11e-06	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.27e-06	9.03e-06	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—ALB—hematologic cancer	1.25e-06	8.91e-06	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PTEN—hematologic cancer	1.24e-06	8.81e-06	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—HRAS—hematologic cancer	1.22e-06	8.71e-06	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—AKT1—hematologic cancer	1.21e-06	8.62e-06	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—AKT1—hematologic cancer	1.21e-06	8.59e-06	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.2e-06	8.52e-06	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—AKT1—hematologic cancer	1.19e-06	8.45e-06	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—AKT1—hematologic cancer	1.18e-06	8.44e-06	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—EP300—hematologic cancer	1.18e-06	8.4e-06	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—IL6—hematologic cancer	1.17e-06	8.34e-06	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.1e-06	7.87e-06	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—AKT1—hematologic cancer	1.08e-06	7.69e-06	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.03e-06	7.34e-06	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PTEN—hematologic cancer	9.54e-07	6.8e-06	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—EP300—hematologic cancer	9.1e-07	6.48e-06	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PIK3CA—hematologic cancer	8.72e-07	6.22e-06	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—AKT1—hematologic cancer	8.41e-07	5.99e-06	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—AKT1—hematologic cancer	7.12e-07	5.08e-06	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PIK3CA—hematologic cancer	6.73e-07	4.8e-06	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—AKT1—hematologic cancer	5.5e-07	3.92e-06	CbGpPWpGaD
